AstraZeneca and Targacept's experimental Alzheimer's disease drug AZD3480 failed to improve symptoms more than a placebo in a study.
The results ``were affected by the fact that the placebo group showed unexpected improvement over the treatment time, rather than the expected decline.''
More at Bloomberg
Insider's view: Hmmm. Makes you wonder about the trials that showed a positive effect.....
2 comments:
FYI: In the U.S., a pending drug has to have two studies showing any degree of superiority over a placebo in order to file a new drug application or receive a new indication in the future. Yet the same pending drug can have many studies under its history that show no benefit, or even negative benefits. Of course, it would be ridiculous to compare a pending drug with another comparable drug. I mean, we are talking about investors here.
So what about those "non-inferiority" studies? What allows _those_ to fly?
Post a Comment